絞り込み

16645

広告

The De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Prognosticator in Patients With End-stage Renal Disease-associated Renal Cell Carcinoma.

著者 Ikeda T , Ishihara H , Takagi T , Fukuda H , Yoshida K , Iizuka J , Kobayashi H , Okumi M , Ishida H , Kondo T , Tanabe K
Clin Genitourin Cancer.2019 Dec 17 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (7view , 0users)

Full Text Sources

The aspartate transaminase (AST)/alanine transaminase (ALT) ratio (ie, the De Ritis ratio) is associated with prognosis in some types of cancers including renal cell carcinoma (RCC). Meanwhile, an effective prognosticator for end-stage renal disease (ESRD)-associated RCC remains unknown. Thus, we investigated the prognostic impact of the AST/ALT ratio in patients with ESRD-associated RCC.
PMID: 31917171 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード